Novel Diagnostics for Ocular Structure
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
| Condition |
|---|
|
Glaucoma Macular Disease |
| Study Type: | Observational |
| Official Title: | Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure |
| Estimated Enrollment: | 500 |
| Study Start Date: | January 1995 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Recruiting subjects male or female, ages beginning at 18 with Macular dgegeneration, diabetic retinopathy, and/or glaucoma. Can also be a normal/healthy subject.
Inclusion Criteria:
- Age older than or equal to 18 years old
- Macular Degeneration, Diabetic Retinopathy, and/or glaucoma patients.
- Normal control subjects
Exclusion Criteria:
- Media opacity (lens, vitreous, cornea)
- Strabismus, nystagmus, or a condition that would prevent fixation.
- Inability to understand informed consent
Contacts and Locations| Contact: Kristy A Truman | 412-383-8778 | trumank@upmc.edu |
| Contact: Melessa Salay | 412-383-9884 | salaymd@upmc.edu |
| United States, Pennsylvania | |
| University of Pittsburgh UPMC Eye Center | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Kristy A Truman 412-383-8778 trumank@upmc.edu | |
| Contact: Rose Clare Aubourg 412-383-3853 | |
| Sub-Investigator: Joel S Schuman, MD | |
| Principal Investigator: Gadi Wollstein, MD | |
| Sub-Investigator: Hiroshi Ishikawa, MD | |
| Study Chair: | Joel S Schuman, MD | University of Pittsburgh |
More Information
No publications provided by University of Pittsburgh
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Joel Schuman M.D. / Melessa Salay, UPMC Eye Center |
| ClinicalTrials.gov Identifier: | NCT00286637 History of Changes |
| Other Study ID Numbers: | RO1-EY013178-06, RO1-EY011289-21, P30-EY008098 |
| Study First Received: | February 2, 2006 |
| Last Updated: | July 25, 2011 |
| Health Authority: | United States: Institutional Review Board United States: Food and Drug Administration |
Keywords provided by University of Pittsburgh:
|
OCT CSLO SLP Perimetry electrophysiology |
glaucoma macular degeneration retinopathy diabetes macular hole |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases |
ClinicalTrials.gov processed this record on May 22, 2013